Clinical Trial Search

Primary: To Evaluate the Incidence of the Pre-proendothelin SNP at Nucleotide 5665 — 10 participants

Primary: Feasibility of Pacemaker Implant With Total Thoracoscopic Approach to Epicardial Pacing Lead — 100 percentage of particiapants

Primary: Cardiac Index — 3.39; 3.42; 3.23 L/min/m2

Primary: Recurrence of Advanced Heart Block — 5 Participants

Primary: Mean Difference in Stroke Volume Between CMR and SMIC — 1.7 ml — p=0.47

Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec

Primary: BNP Levels — 16.3; 42.4; 384.3 pg/ml

Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039

Primary: Moderate to Vigorous Physical Activity (MVPA) — -1.9; 3.4 average minutes per day — p=0.24

Primary: Transition Readiness Assessment Questionnaire (TRAQ) Score — 2.77; 2.95; 3.80; 3.92 units on a scale

Primary: Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection, Serious Arrhythmia and/or Death — 303; 349 participants

Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants

Primary: Feasibility Evaluation and Major Cardiac Adverse Events Related to Transcoronary Infusion of Cardiac Progenitor Cells — 0; 0 participants

Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants

Primary: Left Ventricular Mass Index — 67; 60 g/m2 — p=0.27

Primary: Extracellular Volume Fraction — 30.1; 25.3 percentage of myocardium

Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants

Primary: Coronary Flow Reserve (CFR) — 1.77 ratio: peak to baseline CFV

Primary: Acetaminophen Serum Concentrations — 19; 17; 13; 13 mcg/mL

Primary: Feasibility of Enrollment — 40; 38 Participants

Primary: Acceptability Measured by the Client Satisfaction Questionnaire — 30.57 score on a scale

Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001

Primary: The Number of Graft Related Post-operative Complications That Require a Repeat Surgery or a Non Surgical Treatment Within 12-month Post Implantation. — 0 Participants

Primary: H01: All Cause Mortality — 244; 218 participants — p=0.12

Primary: Number of Subjects Who Completed 24 Weeks of Therapy — 0; 1 Participants

Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44

Primary: Moderate to Vigorous Physical Activity (MVPA) — -0.7; 8.8 Average change in minutes per day — p=.023

Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants

Primary: Number of Incidence of Treatment Related Major Adverse Cardiac Events — 1; 0; 6 Events